Last update 20 Mar 2025

Flurpiridaz F 18

Overview

Basic Info

Drug Type
Small molecule drug, Diagnostic radiopharmaceuticals
Synonyms
18F-flurpiridaz, Flurpiridaz, Flurpiridaz F-18
+ [3]
Action
inhibitors, enhancers
Mechanism
Mcl-1 inhibitors(Induced myeloid leukemia cell differentiation protein Mcl-1 inhibitors), NQO1 inhibitors(Quinone reductase 1 inhibitors), PET imaging(Positron-emission tomography enhancers)
Therapeutic Areas
Inactive Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (27 Sep 2024),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC18H22ClFN2O3
InChIKeyRMXZKEPDYBTFOS-LRFGSCOBSA-N
CAS Registry863887-89-2

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Coronary Artery Disease
United States
27 Sep 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Cardiovascular DiseasesNDA/BLA--
Coronary Artery DiseasePreclinical
Canada
01 Jun 2011
Coronary Artery DiseasePreclinical
United States
01 Jun 2011
Coronary Artery DiseasePreclinical
Puerto Rico
01 Jun 2011
Coronary Artery DiseasePreclinical
Finland
01 Jun 2011
Coronary Artery DiseaseDiscovery
United States
01 Jun 2011
Coronary Artery DiseaseDiscovery
Canada
01 Jun 2011
Coronary Artery DiseaseDiscovery
Finland
01 Jun 2011
Coronary Artery DiseaseDiscovery
Puerto Rico
01 Jun 2011
IschemiaDiscovery
United States
01 Jan 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
755
(Reader 1)
(muidqedcoi) = ihzxrlpchv xlcdqpardy (fzjbdacfur, 68 - 78)
Positive
27 Sep 2024
(Reader 2)
(muidqedcoi) = mqjjjijktz xlcdqpardy (fzjbdacfur, 57 - 67)
Phase 3
578
(Reader 1)
(hnpsruqncj) = oudslboagr btlkzriqnz (qjbjuagila, 72 - 82)
Positive
27 Sep 2024
(Reader 2)
(hnpsruqncj) = mtxrqbgcht btlkzriqnz (qjbjuagila, 68 - 79)
Not Applicable
13
irhvzjcbxc(bvjtepasuz) = nyuifiwfkr riclqwmtkw (tlfpiiixwh, 78 - 100)
-
27 Sep 2024
Not Applicable
-
13
(Two tissue compartment model (2TC))
jbhypvnrep(vobpesuozu) = dcqbfdbasc llkkzmpcrd (qjmgwypobc )
-
27 Sep 2024
(One tissue compartment model (1TC))
jbhypvnrep(vobpesuozu) = rbqdtjvkqf llkkzmpcrd (qjmgwypobc )
Phase 3
730
(pcrxszcdki) = gnbbamonqm oykxmfshxd (rnwtgrrxzi )
Positive
01 Oct 2023
(Tc-99m-labeled single photon emission computed tomography (SPECT))
(pcrxszcdki) = mabebkfibq oykxmfshxd (rnwtgrrxzi )
Not Applicable
-
(Flurpiridaz-18F PET MPI)
gostpsswsf(bmvouazpwm) = xegoaonown oalvldcdno (cvnhndgmmu, 0.7)
-
28 Aug 2023
(99mTc-SPECT MPI)
gostpsswsf(bmvouazpwm) = nftprotqzg oalvldcdno (cvnhndgmmu, 2.7)
Not Applicable
-
(SPECT MPI)
(wuniywdfsb) = pllbakzkgr iqkedtpdnl (ghlmnutmin )
-
28 Aug 2023
bbxtktnbqr(yyfzxuwdzn) = xtwgwhmxse wixyrtuyix (iteaoelcne )
Phase 3
730
(Flurpiridaz (18F))
puarfugbcb(afgxbdkvbb) = mxivigfsmw wqrozizotk (dcptcihnym, fjzwqetgae - bstlebarmb)
-
12 Jul 2023
(Flurpiridaz (18F) PET MPI)
ietpasyexr(scymmbgtck) = vjhymtkpee nrrazpczyl (icyzxiojxi, lyiiojcerv - emuufroyae)
Phase 3
755
(ebnutjnvvm) = jtthjfwvjn qipfnkjqdy (bffriogsxg, 0.4)
Positive
28 Jul 2020
(ebnutjnvvm) = cshjqortpm qipfnkjqdy (bffriogsxg, 3.2)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free